Compare OLPX & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLPX | NBTX |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2018 |
| Metric | OLPX | NBTX |
|---|---|---|
| Price | $2.04 | $31.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $1.89 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 3.7M | 41.8K |
| Earning Date | 05-05-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $422,960,000.00 | N/A |
| Revenue This Year | $2.95 | $58.17 |
| Revenue Next Year | $3.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.07 | N/A |
| 52 Week Low | $0.99 | $3.30 |
| 52 Week High | $2.04 | $41.89 |
| Indicator | OLPX | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 46.22 |
| Support Level | $2.02 | $29.30 |
| Resistance Level | $2.04 | $34.66 |
| Average True Range (ATR) | 0.01 | 1.50 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 75.00 | 13.79 |
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.